In view of this, bone marrow mesenchymal stem cell (BM-MSC) Exos were loaded with galectin-9 siRNA by electroporation and modified with oxaliplatin (OXA) prodrug as an immunogenic cell death trigger to disrupt tumor immunosuppression by M2 TAMs and recruit cytotoxic T lymphocytes, achieving significant therapeutic efficacy in the immunotherapy of pancreatic ductal adenocarcinoma (128). This evidence concerns the gene LGALS9 and neoplasm.